Expression of Monocarboxylate Transporter 1 in Oral and Ocular Canine Melanocytic Tumors
2007; SAGE Publishing; Volume: 44; Issue: 4 Linguagem: Inglês
10.1354/vp.44-4-449
ISSN1544-2217
AutoresY. Shimoyama, Y. Akihara, Doaa Kirat, Hidetomo Iwano, K. Hirayama, Yumiko Kagawa, Tetsuo Ohmachi, Kenichi Matsuda, M. Okamoto, Tsuyoshi KADOSAWA, Hiroshi Yokota, Hiroyuki TANIYAMA,
Tópico(s)Virus-based gene therapy research
ResumoSolid tumors are composed of a heterogeneous population of cells surviving in various concentrations of oxygen. In a hypoxic environment, tumor cells generally up-regulate glycolysis and, therefore, generate more lactate that must be expelled from the cell through proton transporters to prevent intracellular acidosis. Monocarboxylate transporter 1 (MCT1) is a major proton transporter in mammalian cells that transports monocarboxylates, such as lactate and pyruvate, together with a proton across the plasma membrane. Melanocytic neoplasia occurs frequently in dogs, but the prognosis is highly site-dependent. In this study, 50 oral canine melanomas, which were subdivided into 3 histologic subtypes, and 17 ocular canine melanocytic neoplasms (14 melanocytomas and 3 melanomas) were used to examine and compare MCT1 expression. Immunohistochemistry using a polyclonal chicken anti-rat MCT1 antibody showed that most oral melanoma exhibited cell membrane staining, although there were no significant differences observed among the 3 histologic subtypes. In contrast, the majority of ocular melanocytic tumors were not immunoreactive. Additionally, we documented the presence of a 45-kDa band in cell membrane protein Western blots, and sequencing of a reverse transcriptase polymerase chain reaction band of expected size confirmed its identity as a partial canine MCT1 transcript in 3 oral tumors. Increased MCT1 expression in oral melanomas compared with ocular melanocytic tumors may reflect the very different biology between these tumors in dogs. These results are the first to document canine MCT1 expression in canine tumors and suggest that increased MCT1 expression may provide a potential therapeutic target for oral melanoma.
Referência(s)